A review of the psychometric performance of the EQ-5D in people with urinary incontinence

Health and Quality of Life Outcomes

Volumn 11, Issue 1, 2013, Pages

  Davis, Sarah ^a   Wailoo, Allan ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

EQ 5D; Psychometrics; Quality adjusted life years; Quality of life; Urinary incontinence; Utility

Indexed keywords

BIOSIS; CINAHL; COCHRANE LIBRARY; EMBASE; EQ 5D; HUMAN; MEDLINE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PSYCHOMETRY; PSYCINFO; QUALITY OF LIFE; RELIABILITY; REVIEW; SYSTEMATIC REVIEW; URINE INCONTINENCE; VALIDITY;

COST-BENEFIT ANALYSIS; FEMALE; HUMANS; PSYCHOMETRICS; QUALITY INDICATORS, HEALTH CARE; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; URINARY INCONTINENCE;

EID: 84873939355     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-11-20     Document Type: Review

References (25)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub committee of the International Continence Society. Neurourol Urodyn 2002, 21:167-178. 10.1002/nau.10052, 11857671.
2. Hawthorne G. Assessing utility where short measures are required: development of the short assessment of quality of life-8 (AQoL-8) instrument. Value Health 2009, 12:948-957. 10.1111/j.1524-4733.2009.00526.x, 19490558.
3. Norton PA, MacDonald LD, Sedgwick PM, Stanton SL. Distress and delay associated with urinary incontinence, frequency, and urgency in women. Br Med J 1988, 297:1187-1189.
4. Martin JL, Williams KS, Abrams KR, Turner DA, Sutton AJ, Chapple C, Assassa RP, Shaw C, Cheater F. Systematic review and evaluation of methods of assessing urinary incontinence. Health Technol Assess 2006, 10:1-132. iii-iv.
5. National Institute for Health and Clinical Excellence (NICE) Guide to the methods of technology appraisal 2008, London: NICE, National Institute for Health and Clinical Excellence (NICE).
6. Brazier J, Deverill M. A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Health Econ 1999, 8:41-51. 10.1002/(SICI)1099-1050(199902)8:1<41::AID-HEC395>3.0.CO;2-#, 10082142.
7. Haywood KL, Garratt AM, Lall R, Smith JF, Lamb SE. EuroQol EQ-5D and condition-specific measures of health outcome in women with urinary incontinence: reliability, validity and responsiveness. Qual Life Res 2008, 17:475-483. 10.1007/s11136-008-9311-z, 18274881.
8. Donovan JL, Kay HE, Peters TJ, Abrams P, Coast J, Matos-Ferreira A, Rentzhog L, Bosch JL, Nordling J, Gajewski JB, et al. Using the ICSOoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' study. International continence society--benign prostatic hyperplasia. Br J Urol 1997, 80:712-721. 10.1046/j.1464-410X.1997.00461.x, 9393291.
9. Saarni SI, Härkänen T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A, Lönnqvist J. The impact of 29 chronic conditions on health-related quality of life: a general population survey in finland using 15D and EQ-5D. Qual Life Res 2006, 15:1403-1414. 10.1007/s11136-006-0020-1, 16960751.
10. Currie CJ, McEwan P, Poole CD, Odeyemi IAO, Datta SN, Morgan CL. The impact of the overactive bladder on health-related utility and quality of life. BJU Int 2006, 97:1267-1272. 10.1111/j.1464-410X.2006.06141.x, 16686724.
11. Noble SM, Coast J, Brookes S, Neal DE, Abrams P, Peters TJ, Donovan JL. Transurethral prostate resection, noncontact laser therapy or conservative management in men with symptoms of benign prostatic enlargement: an economic evaluation. J Urol 2002, 168:2476-2482. 10.1016/S0022-5347(05)64172-9, 12441944.
12. Monz B, Chartier-Kastler E, Hampel C, Samsioe G, Hunskaar S, Espuna-Pons M, Wagg A, Quail D, Castro R, Chinn C, et al. Patient characteristics associated with quality of life in European women seeking treatment for urinary incontinence: results from PURE. Eur Urol 2007, 51:1073-1081. 10.1016/j.eururo.2006.09.022, 17081676.
13. Monz B, Pons ME, Hampel C, Hunskaar S, Quail D, Samsioe G, Sykes D, Wagg A, Papanicolaou S. Patient-reported impact of urinary incontinence-results from treatment seeking women in 14 European countries. Maturitas 2005, 52(Suppl 2):S24-S34.
14. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997, 50:100-107.
15. Johannesson M, O'Conor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997, 80:557-562. 10.1046/j.1464-410X.1997.00420.x, 9352692.
16. Ismail SI, Forward G, Bastin L, Wareham K, Emery SJ, Lucas M. Extracorporeal magnetic energy stimulation of pelvic floor muscles for urodynamic stress incontinence of urine in women. J Obstet Gynaecol 2009, 29:35-39. 10.1080/01443610802484393, 19280493.
17. Dumville JC, Manca A, Kitchener HC, Smith AR, Nelson L, Torgerson DJ, COLPO Study Group Cost-effectiveness analysis of open colposuspension versus laparoscopic colposuspension in the treatment of urodynamic stress incontinence. BJOG 2006, 113:1014-1022. 10.1111/j.1471-0528.2006.01036.x, 16956333, COLPO Study Group.
18. Manca A, Sculpher MJ, Ward K, Hilton P. A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. BJOG 2003, 110:255-262.
19. Tincello D, Sculpher M, Tunn R, Quail D, van der Vaart H, Falconer C, Manning M, Timlin L. Patient characteristics impacting health state index scores, measured by the EQ-5D of females with stress urinary incontinence symptoms. Value Health 2010, 13:112-118. 10.1111/j.1524-4733.2009.00599.x, 19744293.
20. Ternent L, Vale L, Buckley B, Glazener C. Measuring outcomes of importance to women with stress urinary incontinence. BJOG 2009, 116:719-725. 10.1111/j.1471-0528.2008.02106.x, 19298440.
21. Kobelt G, Fianu-Jonasson A. Treatment of stress urinary incontinence with non-animal stabilised hyaluronic acid/dextranomer (NASHA/Dx) gel: an analysis of utility and cost. Clin Drug Investig 2006, 26:583-591. 10.2165/00044011-200626100-00005, 17163292.
22. Rinne K, Laurikainen E, Kivelä A, Aukee P, Takala T, Valpas A, Nilsson CG. A randomized trial comparing TVT with TVT-O: 12-month results. International Urogynecology Journal 2008, 19:1049-1054.
23. Mihaylova B, Pitman R, Tincello D, Van DV Tunn R, Timlin L, Quail D, Johns A, Sculpher M. Cost-effectiveness of duloxetine: the stress urinary incontinence treatment (SUIT) study. Value Health 2010, 13:565-572. 10.1111/j.1524-4733.2010.00729.x, 20456715.
24. EuroQol Group website EuroQol group Website http://www.euroqol.org/eq-5d-products.html, EuroQol Group website.
25. Lin FJ, Longworth L, Pickard AS. Evaluation of content on EQ-5D as compared to disease-specific utility measures. Qual Life Res 2012, 1-22.